Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -1,3 (-2,1)
- Earnings per share* SEK -0.06 (-0.11)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.
Summary of the financial year (2021-07-01 - 2022-06-30)- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -4,9 (-5,3)
- Earnings per share* SEK -0.25 (-0.31)
- Cash and cash equivalents at the end of the period amounted to MSEK 25,2 (35,5)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 16,790,364. Amounts in brackets refer to the corresponding period last year.
CEO's comment
The company's phase 1 study regarding OsteoDex's treatment of multiple myeloma is underway and patient recruitment is ongoing.
The principal investigator (PI) is Dr. Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital, Huddinge. Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. Patients with relapsed/treatment-resistant disease and who have received 1-3 previous lines of treatment are included. The primary objective is to confirm safety and tolerability and, as a secondary objective, to determine any treatment response. Documentation of quality of life will also be done (QoL scores).
Study material, GMP manufactured OsteoDex, is produced by Biovian OY, Turku, Finland and is delivered to the respective hospitals. We look forward to conducting this study.
Anders R Holmberg
Contact
Anders Holmberg, CEO, +46 73 324 27 82
Gösta Lundgren, CFO, +46 70 710 47 88
This information is such information that DexTech Medical AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on August 30, 2023 through the care of the above contact persons.
DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to outlicense each drug candidate no later than after the completed phase II study. DexTech Medical AB is listed on Spotlight Stock Market.